Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 128   

Articles published

NVO 54.77 -0.20 (-0.36%)
price chart
Novo Nordisk And Eli Lilly Battling To Win GLP-1 Drug Market
Diabetes patients have a multitude of therapy options available, ranging from tablets and insulin therapies to the less common glucagon-like peptide-1 (GLP-1) agonists.
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate ...
Another major hedge fund that recently disclosed its long equity positions for the second quarter of 2014 is Jim Simons' Renaissance Technologies, one of the best performing firms in the sector.
Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis ...
Novo Nordisk A/S (NYSE: NVO) is the undisputed global leader in the diabetes market. The company's impressive product portfolio is home to five of the world's 10 best-selling diabetes medications.
Related articles »  
Is Novo Nordisk A/S (ADR) (NVO) Going to Burn These Hedge Funds?
In the 21st century investor's toolkit, there are a multitude of metrics investors can use to track Mr. Market. A couple of the most under-the-radar are hedge fund and insider trading movement.
Related articles »  
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
The drug was run for non-inferiority tests against Novo's older insulin, Levemir. Moreover, both Levemir and Tresiba were combined to form mealtime insulin called Aspart or NovoRapid, which was commercialized in Europe.
Related articles »  
Novo Nordisk's (NVO) Diabetes Drug Victoza Receives Positive Review By CHMP
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Friday that its key drug Victoza has received positive reviews from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes ...
Related articles »  
Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And Vivus's ...
Novo Nordisk A/S (ADR) (NVO) received the Food and Drug Administration's (FDA) approval on September 11 for its weight-loss therapy Saxenda, which was earlier prescribed as a treatment for diabetes.
Related articles »  
Novo Nordisk A/S (ADR) (NVO): Insiders Aren't Crazy About It
Novo Nordisk A/S (ADR) (NYSE:NVO) was in 13 hedge funds' portfolio at the end of the first quarter of 2013. NVO shareholders have witnessed a decrease in support from the world's most elite money managers lately.
In A World of Cheap Oil, Europe Looks Good [iShares MSCI Sweden Index (ETF ...
europe Martin Hutchinson: The halving in oil prices is the biggest economic change we have seen since the 2008 financial crash. There are winners and losers everywhere from it, but there's one standout winner: the European Union, which produces only ...